The global small molecule CMO/CDMO market is on a robust growth trajectory, according to the latest analysis from Future Market Insights (FMI). The report highlights an impressive projected Compound Annual Growth Rate (CAGR) of 5.2% from 2024 to 2034, with the market anticipated to reach an estimated value of approximately USD 74,998.1 million in 2024 and achieve a valuation of USD 124,532.4 million by the end of the forecast period.
Small-molecule Active Pharmaceutical Ingredients (APIs) are crucial to the pharmaceutical industry, serving as the active therapeutic components in a wide range of medications. These APIs are characterized by their low molecular weights and chemical synthesis, providing targeted therapeutic effects through specific interactions with biological processes.
The FMI report underscores the critical role of small molecule CMO/CDMO services in addressing the growing demand for small-molecule APIs globally. With pharmaceutical companies increasingly turning to outsourcing to streamline their operations, enhance flexibility, and access specialized expertise, the small molecule CMO/CDMO market is experiencing notable growth. This trend reflects a broader industry shift towards leveraging external partners for efficiency and innovation.
As the market expands, small molecule CMO/CDMO providers are expected to play a pivotal role in supporting the pharmaceutical industry’s evolving needs, ensuring the efficient production and development of essential small-molecule APIs.
Key factors driving the growth of the global small molecule CMO/CDMO market include:
- Rising Demand for Customized Drug Development: The growing need for tailored therapeutic solutions and personalized medicine is propelling the demand for small molecule CMO/CDMO services, enabling pharmaceutical companies to develop niche products with precision.
- Advancements in Pharmaceutical Technologies: Technological advancements, particularly in synthetic chemistry, process optimization, and analytical methodologies, are bolstering the efficiency and cost-effectiveness of small molecule CMO/CDMO operations, driving market expansion.
- Increasing Focus on API Manufacturing Outsourcing: Pharmaceutical companies are increasingly outsourcing API manufacturing to specialized CMOs/CDMOs to capitalize on their expertise, infrastructure, and regulatory compliance, fostering market growth.
- Expanding Biopharmaceutical Pipeline: The burgeoning pipeline of small-molecule drugs, coupled with patent expirations and generic competition, is fueling demand for CMO/CDMO services for API development, manufacturing, and formulation.
Future Market Insights’ comprehensive analysis offers valuable insights for stakeholders, including small molecule CMOs/CDMOs, pharmaceutical companies, investors, and regulatory authorities, to capitalize on emerging opportunities and navigate challenges in the evolving landscape.
Key Takeaways from the Small Molecule CMO/CDMO Market Study:
- By product, the standard API segment held a lucrative small molecule CMO/CDMO market share of 7% in 2023.
- By service, the process development segment is expected to hold over 8% market value share by the end of 2034.
- By company size, the mid-sized company segment is set to progress at a 8% CAGR, totaling a valuation of USD 55,615.8 million by 2033.
- By the scale of operation, the commercial segment is set to expand at a high CAGR of 6%, totaling USD 90,027.3 million in 2033.
- East Asia is considered the leading region, with a value share of 0% at the end of the forecast period.
Small Molecule CMO/CDMO Trends: Find Out More in Our Comprehensive Report Filled with Key Insights!
Competitive Landscape:
Acquisition and expansion among leading companies or brands is the key strategy of renowned manufacturers in the global small molecule CMO/CDMO market. Companies such as Ajinomoto Bio-Pharma Services and Asymchem are aiming to enhance their presence in the market and compete with other players during the estimated years.
Key Companies Profiled:
- Pfizer CentreOne
- Baxter BioPharma Solutions
- Catalent
- Lonza
- Syngene International
- Boehringer Ingelheim
- Piramal Pharma Solutions
- Wuxi AppTec
- Patheon (Thermo Fisher Scientific Inc.)
- Adare Pharma Solutions
- Ajinomoto Bio-Pharma Services
- Ascendia Pharma
- Asymchem
- August Bioservices
- Cambrex
- Nanoform
- PCI Pharma Services
- Quotient Sciences
- Societal™ CDMO
- Siegfried Holding AG
- Corden Pharma International
Following are a handful of examples of acquisitions made by them to be at the top position:
- In August 2020, Ajinomoto Bio-Pharma Services added a new 8,500-square-meter production facility to its Visakhapatnam, India site, increasing its capability for manufacturing small molecules.
- In November 2022, Snapdragon Chemistry, a United States-based chemical technology company that offers experience in continuous manufacturing and early-stage chemical process development services to the pharmaceutical and fine chemical industries, was acquired by Asymchem. It is a contract development and manufacturing organization (CDMO) catering to the global pharmaceutical and biotech industry.
Key Market Segments Covered in Small Molecule CMO/CDMO Industry Research:
By Product:
- Standard API
- HPAPI
By Service:
- Process Development
- Analytical Method Development
- GMP Manufacturing Service
- Scale-Up and Tech Transfer
- Quality Control and Quality Assurance
- Regulatory Assistance
- Technology and Innovation
By Company Size:
- Large
- Mid-sized
- Small
By Scale of Operation:
- Clinical
- Phase I
- Phase II
- Phase III
- Commercial
By Region:
- North America
- East Asia
- Western Europe
- Eastern Europe
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
